Eric Venker
President bei ROIVANT SCIENCES LTD.
Vermögen: 5 Mio $ am 31.03.2024
Profil
Derzeit ist Eric Venker Co-President & Chief Operating Officer bei Roivant Sciences Ltd, President & Chief Operating Officer bei Roivant Sciences, Inc. und Co-President & Chief Operating Officer bei Roivant Sciences GmbH (beides Tochtergesellschaften von Roivant Sciences Ltd.) sowie Co-President & Chief Operating Officer bei Montes Archimedes Acquisition Corp. Eric Venker ist außerdem Mitglied des Verwaltungsrats von Arbutus Biopharma Corp., Sio Gene Therapies, Inc., Aruvant Sciences, Inc. und Immunovant, Inc. Zuvor war er Vorsitzender des Housestaff Quality Council am Columbia University Medical Center. Eric Venker hat einen Doktortitel der Yale School of Medicine und einen Doktortitel des St. Louis College of Pharmacy.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ROIVANT SCIENCES LTD.
0,06% | 20.04.2024 | 484 200 ( 0,06% ) | 5 Mio $ | 31.03.2024 |
Aktive Positionen von Eric Venker
| Unternehmen | Position | Beginn |
|---|---|---|
| IMMUNOVANT, INC. | Director/Board Member | 18.02.2020 |
| ROIVANT SCIENCES LTD. | President | 01.01.2021 |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | President | 01.01.2021 |
Aruvant Sciences, Inc.
 Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Director/Board Member | - |
Roivant Sciences GmbH
 Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Roivant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in Basel, Switzerland. | Chief Operating Officer | - |
| Roivant Social Ventures, Inc. | Director/Board Member | 01.01.2014 |
Ehemalige bekannte Positionen von Eric Venker
| Unternehmen | Position | Ende |
|---|---|---|
| SIO GENE THERAPIES INC. | Director/Board Member | 05.04.2023 |
| ARBUTUS BIOPHARMA CORPORATION | Director/Board Member | 25.05.2022 |
| ROIVANT SCIENCES LTD. | President | - |
| ░░░░░░░░ ░░░░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Eric Venker
| St. Louis College of Pharmacy | Doctorate Degree |
| Yale School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| ROIVANT SCIENCES LTD. | Health Technology |
| IMMUNOVANT, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Roivant Sciences GmbH
Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Roivant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in Basel, Switzerland. | Health Technology |
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY. | Health Technology |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Health Technology |
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Health Technology |
Montes Archimedes Acquisition Corp.
 Montes Archimedes Acquisition Corp. Financial ConglomeratesFinance Montes Archimedes Acquisition Corp operates as a blank check company. It is formed for the business purpose to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded James C. Momtazee and Maria C. Walker on July 6, 2020 and is headquartered in Menlo Park, CA. | Finance |
| Roivant Social Ventures, Inc. |
